Background: The inhibitory receptor programmed cell death protein 1 (PD-1) is upregulated on a variety of immune cells, including natural killer (NK) cells, during chronic viral infection and tumorigenesis. Blockade of PD-1 or its ligands produces durable clinical responses with tolerable side effects in patients with a broad spectrum of cancers. However, the underlying molecular mechanisms of how PD-1 regulates NK cell function remain poorly characterized. Objective: We sought to determine the effect of PD-1 signaling on NK cells. Methods: PD-1 was overexpressed in CD16-KHYG-1 (a human NK cell line with both antibody-dependent cellular cytotoxicity through CD16 and natural cytotoxicity through NKG2D) cells and stimulated by exposing the cells to NK-sensitive target cells expressing programmed death ligand 1 (PD-L1). Results: PD-1 engagement by PD-L1 specifically blocked NK cell-mediated cytotoxicity without interfering with the conjugation between NK cells and target cells. Further examination showed that PD-1 signaling blocked lytic granule polarization in NK cells, which was accompanied by failure of integrin-linked kinase, a key molecule in the integrin outside-in signaling pathway, to accumulate in the immunological synapse after NK-target cell conjugation. Conclusion: Our results suggest that NK cell cytotoxicity is inhibited by PD-1 engagement, which blocks lytic granule polarization to the NK cell immunological synapse with concomitant impairment of integrin outside-in signaling. This study provides novel mechanistic insights into how PD-1 inhibition disrupts NK cell function. (J Allergy Clin Immunol 2018;142:1311-21.) 
Since programmed cell death protein 1 (PD-1; also known as CD279) was discovered in 1992, 1 pathway blockade of PD-1 and its ligands, including programmed death ligand 1 (PD-L1; also called CD274 and B7-H1) and PD-L2 (also called CD273 and B7-DC), have been exploited in a wide variety of potential applications to treat cancers, 2,3 viral infections, 4 autoimmune diseases, 5 and many other diseases. 6, 7 The roles of PD-1 in T cell-and B cell-mediated immune responses have been well characterized in the field of basic immunology. 8 PD-1 signaling can protect against tissue damage and autoimmune diseases by inducing and maintaining T-cell tolerance 8 and by inhibiting self-reactive T cells, 5 respectively. However, PD-1 signaling can be harmful because it is the major cause of effector cell exhaustion during long-term, chronic antigen stimulation. 8 Specifically, PD-1 signaling blocks T-cell functions, including proliferation, 9 cytokine (eg, IL-2) production, 10 adhesion, 11 and cytotoxicity. 12 The underlying molecular basis for using PD-1 pathway blockade is that suppression of PD-1 signaling allows activation of tumor-specific cytotoxic T cells or other effector cells (eg, natural killer [NK] cells) by removing the cytotoxic lymphocyte activation ''brake'' and modifying the tumor microenvironment. 2, 13 PD-1 is expressed on a variety of immune cells, including activated and/or exhausted T and B cells, activated monocytes, dendritic cells, 8 regulatory T cells, 14 and NK cells. [15] [16] [17] [18] NK cells provide the first line of defense to cancer and viral infection. 19, 20 For effective elimination of virus-infected cells or tumor cells, NK cells have to integrate both activation receptor signaling and inhibitory receptor signaling. 20, 21 However, despite the importance of NK cells in combating diseases, the precise mechanisms whereby PD-1 mediates its effects on NK cells remains poorly characterized.
Integrins play an important role in NK cell activation, which is mediated by both outside-in (eg, granule polarization) and insideout (eg, conjugation) signals. 22, 23 In T cells T-cell receptor (TCR) signaling alone can induce lytic granule (LG) polarization. 24 TCR signaling also provides strong inside-out signals to leukocyte function-associated antigen 1 (LFA-1; also called a L b 2 integrin). The coengagement of LFA-1 and TCR further enhances the extent of LG polarization induced by the TCR alone. 24 However, in NK cells ligation of LFA-1 with intercellular adhesion molecule 1 (ICAM-1) alone is sufficient to trigger LG polarization. 22, 23 Thus NK cells can serve as a good model system for analysis of outside-in signaling by LFA-1 independently of other signals. 25 A recent study shows that a signaling network centered on an integrin-linked kinase (ILK)-Pyk2-paxillin pathway is required for LG polarization (outside-in). 26 ILK was shown to be recruited to the immunological synapse (IS) by proximity ligation assays, and silencing of ILK impaired polarization of LGs in NK cells. 26 However, it remains unclear whether PD-1 affects integrin signaling in NK cells.
In this study, we investigated the role of PD-1 in human NK cell cytotoxicity. We found that PD-1 activation by PD-L1 blocked NK cell cytotoxicity. However, PD-1 signaling did not inhibit cell-cell conjugation between NK and target cells, an initial step for NKmediated immune responses. In fact, NK cells that expressed PD-1 formed stable inhibitory IS with target cells that expressed PD-L1. Yet LG polarization was blocked, and the integrin outside-in signaling pathway was disrupted by PD-1 engagement.
METHODS

Cell culture
HEK293T cells were maintained in Dulbecco modified Eagle medium (Gibco, Carlsbad, Calif) with 10% FBS (Gibco), 2 mmol/L L-glutamine (Gibco), and 10 mmol/L HEPES (Gibco). K562 and Daudi cell lines (American Type Culture Collection, Manassas, Va) were cultured in R10 medium, which contained RPMI 1640 medium (Gibco) supplemented with 10% FBS, 2 mmol/L L-glutamine, 10 mmol/L HEPES, 1 mmol/L sodium pyruvate (Cellgro, Manassas, Va), and 1% MEM nonessential amino acids solution (Gibco). LG: Lytic granule NK: Natural killer NC: Natural cytotoxicity PD-1: Programmed cell death protein 1 PD-L1: Programmed death ligand 1 TCR: T-cell receptor CD16-KHYG-1, a human NK cell line capable of both antibody-dependent cellular cytotoxicity (ADCC) and natural cytotoxicity (NC), 27 was a gift from Dr David Evans (University of Wisconsin, Madison, Wis) and cultured in R10 medium supplemented with 1 mg/mL cyclosporine (Sigma-Aldrich, St Louis, Mo), 50 mg/mL Primocin (InvivoGen, San Diego, Calif), and 10 U/mL IL-2 (Roche, Mannheim, Germany). All cells were cultured at 378C in a humidified atmosphere with 5% CO 2 . For all experiments, the culture medium of CD16-KHYG-1 cells was replaced to remove cyclosporine 1 day before.
Plasmid constructs and transduction of CD16-KHYG-1, K562, and Daudi cell lines Green fluorescent protein (GFP), PD-1-GFP, mCherry, and PD-L1-mCherry lentiviral plasmids were generated, as previously described. 28 Briefly, to generate the PD-1-GFP construct, the full length of PD-1-GFP (OriGene, Rockville, Md) was subcloned into the lentiviral expression vector pCDH (System Biosciences, Palo Alto, Calif) by using EcoRI and BamHI (Thermo Scientific, Waltham, Mass) insertion sites. To make the C-terminal mCherry-tagged PD-L1 construct, the PD-L1 cDNA (OriGene) was first subcloned into EcoRI-and BamHI-digested pmCherry-N1 vector (Clontech, Mountain View, Calif). The sequence of PD-L1-mCherry was amplified by using PCR and inserted into EcoRI-digested pCDH by using the In-Fusion Cloning System (Clontech). The sequence of turboGFP or mCherry was inserted into pCDH to create the construct for GFP or mCherry, respectively, for lentiviral production and for serving as an experimental control. All plasmids were verified by means of sequencing.
Lentivirus was produced by cotransfecting HEK293T cells with the desired lentiviral vector and 3 packaging plasmids (pMLg/pRRE, pRSV-Rev, and pMD2.g) with Lipofectamine reagent (Invitrogen, Carlsbad, Calif) to generate polyclonal stable cell lines. Briefly, 4 mL of Lipofectamine was mixed with 0.8 mg of total DNA (0.128 mg of desired pCDH construct, 0.32 mg of pMLg/ pRRE, 0.16 mg of pRSV-Rev, and 0.192 mg of pMD2.g) and added into 1 well of HEK293T cells cultured in a 6-well plate at approximately 70% confluence. At 48 hours after transfection, viral particles were harvested by filtering the culture medium through a 0.45-mm filter (GE Healthcare Life Sciences, Pittsburgh, Pa). Then CD16-KHYG-1 cells were infected with 4 mL of virus for GFP or PD-1-GFP, and K562 and Daudi cells were infected with 4 mL of virus for mCherry or PD-L1-mCherry at a density of 5 3 10 4 cells/mL suspended in 4 mL of R10 medium. Transduced cells were cultured for 24 hours in the presence of 8.0 mg/mL Polybrene (Santa Cruz Biotechnology, Dallas, Tex) and subsequently sorted with an Aria II cell sorter (BD Biosciences, San Jose, Calif). Expression of green or red fluorescence in these cells was verified by using flow cytometry with an LSR Fortessa cell analyzer (BD Biosciences). 51 Cr-release assay NK cell cytotoxicity toward K562 or Daudi target cells was examined by using a 51 Cr-release assay, as previously described. 29 Briefly, the target cells were labeled with 51 Cr at 378C for 1 hour. After washing 3 times with fresh R10 medium, cells were resuspended in R10 medium at a density of 1 3 10 5 cells/mL. Aliquots of the target cells (0.1 mL for 1 3 10 4 cells) were mixed with a serial dilution of NK cells, and the mixture was incubated at 378C for 4 hours. For ADCC assays, Daudi cells were incubated with 20 mg/ mL rituximab on ice for 30 minutes before addition of NK cells, and rituximab was also present during the 4-hour incubation at 378C. At the end of the incubation, medium was collected, and radioactivity was measured with a Topcount NXT Scintillation and Luminescence Counter (PerkinElmer, Waltham, Mass 
Conjugation assays
NK-target cell conjugates were measured, as described previously. 23 Immunofluorescence staining NK cells (5 3 10 5 ) and target cells (1 3 10 6 ) were mixed in 500 mL of RPMI 1640 on ice and centrifuged at 48C for 3 minutes at 300 rpm. Samples were kept at 378C for various times. The reaction was stopped by means of gentle pipetting, and the mixture was added to a polylysine-coated slide at 48C for 10 minutes. After the conjugates were attached, medium was removed, and cells were fixed with 4% paraformaldehyde in PBS for 20 minutes. Fixed cells were washed 3 times with PBS and permeabilized with a buffer containing 0.1% Triton X-100 and 5% normal donkey serum before incubation with the primary antibodies at 48C overnight. Cells were washed and probed with fluorophore-conjugated secondary antibodies (Invitrogen) at room temperature for 1.5 hours. When needed, Alexa Fluor-conjugated phalloidin (Invitrogen) was used to stain F-actin. The slide was mounted with a glass coverslip by using ProLong Gold antifade reagent containing 49-6-diamidino-2-phenylindole dihydrochloride (DAPI; Life Technologies, Grand Island, NY).
Laser scanning fluorescence confocal microscopy
Images for both live and fixed cells were acquired with LASAF software (Leica Microsystems, Wetzlar, Germany). For live cell imaging, highresolution images were captured by using a confocal fluorescent microscope (Leica TCS SP8; Leica Microsystems) equipped with a 633 oil immersion objective lens (NA 1.47; Leica Microsystems) at 378C. Fluorescence from GFP and mCherry and bright-field images were detected simultaneously. For fixed cells, 3-dimensional images were reconstructed from acquired z-stacks of X-Y scanning of entire cells for perforin, F-actin, and ILK. ImageJ software (National Institutes of Health, Bethesda, Md) was used for image processing and creating projected images from 3-dimensional reconstructions.
ImageJ and Imaris (Bitplane, Concord, Mass) programs were used to measure the distance between LGs (perforin staining) and the IS (F-actin staining). From the 3-dimensional image, coordinates for the center of all ''dots'' (perforin, x 1 , y 1 , and z 1 ) and that of the ''surface'' (accumulated F-actin, x 2 , y 2 , and z 2 ) were obtained for each conjugate and entered into the following equation:
where D is the average distance of every perforin to the center of the IS for each pair of NK-target cell conjugates.
Antibodies
Antibody sources were as follows: anti-PD-1 (clone 29F.1A12; BioLegend, San Diego, Calif), anti-PD-L1 (clone 10F.9G2; BioLegend), anti-NKG2D (clone 1D11; BioLegend), anti-CD16 (clone 3G8; BioLegend), anti-LFA-1 (clone H155-78; BioLegend), anti-perforin (clone dG9; Thermo Fisher), anti-ILK (clone EPR1592; Abcam, Cambridge, United Kingdom), and anti-actin (clone C4; Santa Cruz Biotechnology).
Statistical analysis
Unpaired or paired 2-tailed t tests were performed with Prism software (GraphPad Software, La Jolla, Calif).
RESULTS
PD-1 signaling attenuates NK cell cytotoxicity
As a first step to understand PD-1 signaling in NK cells, we generated a stable CD16-KHYG-1 cell line expressing PD-1-GFP (NK-PD-1-GFP). CD16-KHYG-1 is a human NK cell line that recognizes and kills target cells, such as K562 and Daudi cells, through 2 distinct mechanisms: NC through activating receptors, such as NKG2D, 30 and ADCC through CD16. 20, 31 To test the NC and ADCC of NK cells in response to PD-1 signaling blockade, K562 and Daudi cell lines stably expressing the PD-1 ligand PD-L1-mCherry (called K562-PD-L1-mCherry and Daudi-PD-L1-mCherry, respectively) were used as target cells. CD16-KHYG-1 and K562 (or Daudi) cell lines stably expressing GFP only or mCherry only (named as NK-GFP, K562-mCherry, and Daudi-mCherry) were used as respective controls. Expression of GFP in the stable CD16-KHYG-1 cell lines and that of mCherry in the stable K562 and Daudi cell lines were verified by using flow cytometry (see Fig E1, left panels, in this article's Online Repository at www.jacionline.org). Using PD-1 and PD-L1 antibodies, we found that more than 95% of cells expressed PD-1 and PD-L1 in the NK-PD-1-GFP and K562-PD-L1-mCherry (or Daudi-PD-L1-mCherry) cells, respectively. However, no PD-1 staining was observed in the parental wild-type CD16-KHYG-1 cells or NK-GFP cells, and no PD-L1 was detected in the wild-type or mCherry-expressing K562 or Daudi cells (see Fig E1, right panels). Thus we successfully established a PD-1-positive NK cell line and PD-L1-positive target cells and their control groups for testing the effects of PD-1 signaling on NK cell cytotoxicity.
We then examined the subcellular distribution of expressed PD-1-GFP and PD-L1-mCherry in transduced cells. Prominent plasma membrane localization and intracellular aggregation of PD-1 and PD-L1 were observed in cells expressing PD-1-GFP and PD-L1-mCherry (see Fig E2, left panels, in this article's Online Repository at www.jacionline.org) but not in cells expressing GFP only and mCherry only (see Fig E2, right panels). The subcellular localization of the expressed PD-1 and PD-L1 in the stable CD16-KHYG-1 and K562 (and Daudi) cells resembled that of endogenous PD-1 in primary T cells, which also showed plasma membrane localization and intracellular aggregation, as reported previously. 32 To test the effect of PD-1 signaling on the cytotoxicity of NK cells, we examined the NC and ADCC of NK-PD-1-GFP cells using a 51 Cr release assay. For NC, NK-GFP and NK-PD-1-GFP cells were coincubated for 4 hours with 51 Cr-loaded K562-mCherry or K562-PD-L1-mCherry cells, whereupon the amount of 51 Cr in the medium was determined. The results showed that coincubation of NK-PD-1-GFP cells with K562-PD-L1-mCherry cells inhibited the cytotoxicity of NK cells against K562 (Fig 1, A) , but NC was unaffected without engagement of PD-1 and PD-L1 (Fig 1, A, and see Fig E3, A, in this article's Online Repository at www.jacionline.org). Similarly, ADCC, as examined by using Daudi-mCherry or Daudi-PD-L1-mCherry cells as NK target cells induced by rituximab (anti-CD20), was abolished only when NK-PD-1-GFP cells were coincubated with Daudi-PD-L1-mCherry cells (Fig 1, B) . Coincubation of CD16-KHYG-1 cells expressing PD-1 with PD-L1-nonexpressing Daudi cells or coincubation of Daudi cells expressing PD-L1 with PD-1-nonexpressing CD16-KHYG-1 cells did not alter ADCC (Fig 1, B , and see Fig E3, B) . Thus the engagement of PD-1 with its natural ligand is required for inhibition of NC and ADCC. PD-1 signaling attenuates NK cell cytotoxicity.
Stable IS is formed in NK cells in the presence of PD-1 signaling
The unaltered killing capability of NK-PD-1-GFP cells on PD-L1-negative target cells indicated that the activating receptors functioned normally in transduced CD16-KHYG-1 cells in the absence of PD-L1. Indeed, using antibody staining, we showed that neither GFP nor PD-1-GFP affected surface expression of NKG2D or CD16 (see Fig E4 in PD-1 mCherry change the expression of these 2 major activating receptors in NK cells.
To further understand the underlying molecular basis of PD-1 inhibition in human NK cells, we investigated the effect of PD-1 signaling on formation of the NK cell IS, a pivotal platform for mediating an effective immune response in both the adaptive and innate immune systems. 28, 33, 34 For cytotoxic killing, an IS forms between the lymphocyte and target cell, where activating receptors accumulate, followed by release of LGs. 35 NK-GFP and NK-PD-1-GFP cells were allowed to form conjugates with K562 or Daudi cells that expressed either mCherry only or PD-L1-mCherry in a 1:1 ratio and were then inspected by using confocal microscopy with live cell imaging to determine whether PD-1 in NK cells binds to PD-L1 from its susceptible target cells at the IS. As shown in Fig 2, PD-1 -GFP accumulated in the IS only when the NK-PD-1-GFP cell was conjugated with a K562 (for examining NC) or CD20 antibody-pretreated Daudi cell (for examining ADCC) that expressed PD-L1-mCherry, which was also concentrated at the IS. The accumulation occurred within minutes and persisted for more than 4 hours (see Video E1 in this article's Online Repository at www.jacionline.org), resembling previous reports for T cells 32, 36 and inhibitory IS formation in NK cells. 28 By contrast, if the target cells expressed mCherry only instead of PD-L1-mCherry, PD-1-GFP did not accumulate at the IS. Conversely, PD-L1-mCherry did not concentrate at the IS without expression of PD-1-GFP in the NK cells (Fig 2) . We also observed a similar phenotype by using PD-1-GFP-infected primary NK cells and K562-PD-L1-mCherry (see Fig E5 in this article' s Online Repository at www.jacionline.org). In conclusion, PD-1 only accumulates at the IS when PD-L1 is present on the target cells for both NC and ADCC.
PD-1 signaling does not affect NK-target cell conjugation
NK cytotoxicity involves multiple distinct steps, including conjugation with target cells, granule polarization, degranulation, and cytotoxic killing. 33 To address this question, we used flow cytometry to determine the percentage of CD16-KHYG-1 cells that were conjugated with target cells. The NK cells (green) were allowed to conjugate with target cells (red) for 5, 10, and 30 minutes and then fixed for testing by using fluorescence-activated cell sorting. Interestingly, no difference in the percentage of GFP and mCherry doublepositive conjugates was observed over the period of 30 minutes in either the NC (Fig 3, A) or ADCC (Fig 3, B) assays among the different combinations of NK and target cells with or without PD-1 and PD-L1 expression (Fig 3) . Together, these results indicate that PD-1/PD-L1 engagement does not affect conjugation of NK cells with their target cells, indicating that PD-1 signaling can affect the downstream steps of NK cytotoxicity.
PD-1/PD-L1 engagement blocks LG polarization at the inhibitory IS of the NK cell
After conjugation with target cells, LGs in NK cells, which contain perforin, become polarized to the IS. 35, 37 This represents another key step in cytotoxic killing. 38 To examine whether engagement of PD-1 and PD-L1 affected LG polarization in NK cells, we measured the distance of perforin to the IS in target-conjugated CD16-KHYG-1 cells that expressed GFP only or PD-1-GFP. Cells were costained for F-actin and perforin, and 3-dimensional fluorescence images of individual cell conjugates were collected by using confocal microscopy. Actin accumulated in the IS of the majority of conjugates we examined with or without PD-1 signaling, indicating that PD-1 signaling does not affect actin accumulation. In these images NK cells were identified by means of positive staining with perforin; the IS was indicated by the accumulated F-actin signal at the boundary between NK and target cells. To quantify the LG polarization, we calculated the distance between perforin and the accumulated F-actin at NK IS (Fig 4) . Additionally, we found that LG polarization occurred between 10 and 30 minutes after conjugation in control groups; however, in the presence of PD-1 signaling, the LGs did not polarize to the IS throughout the 2-hour test period (see Fig E6 in this article' s Online Repository at www.jacionline.org). In both the NC and ADCC models, the distance between the perforin-positive LGs and the IS was significantly longer in conjugates formed between NK-PD-1-GFP cells and target cells that expressed PD-L1-mCherry than that between NK-GFP cells and targets that expressed mCherry at 30 minutes after conjugation (Fig 4) . The finding that LGs did not polarize to the IS at later time points (60 and 120 minutes) in the presence of PD-1 signaling (see Fig  E6) excluded the possibility that granule polarization could still occur during PD-1 engagement with different kinetics. PD-1/ PD-L1 engagement rendered the LGs of the NK cells unable to reach the IS for successful killing of their susceptible target cells. Thus PD-1/PD-L1 engagement specifically blocks LG polarization at the inhibitory NK IS.
PD-1 engagement inhibits integrin signaling
The integrin signaling pathway regulates LG polarization in NK cells. 26 In response to activation of LFA-1 by its ligand, ICAM-1, the LGs along with the microtubule-organizing center in the NK cell polarize toward the target cell. This process requires a signaling network consisting of ILK, Pyk2, paxillin, and several other proteins; ILK also accumulates at the IS in response to NK cell activation. 26 To gain insight into the functional relationship between PD-1/PD-L1 engagement and integrin-mediated adhesion and consequent LG polarization, we costained ILK and perforin in target-conjugated NK-GFP and NK-PD-1-GFP cells (Fig 5, A) . Confocal fluorescence imaging revealed that ILK concentrated in the IS between the majority of conjugated NK-GFP and K562-mCherry cells at 30 and 60 minutes after conjugation (Fig 5, B) , which is indicative of accumulation at the IS. Although the accumulation subsided at 120 minutes in the control groups, ILK appeared, at all the time points we tested, as dispersedly distributed puncta in most of the conjugated NK-PD-1-GFP and K562-PD-L1-mCherry cells (Fig 5, B) . To rule out the possibility of decreased overall expression of integrin molecules on NK cells transduced with PD-1, we measured the mean fluorescence intensity of LFA-1 using flow cytometry and found comparable overall expression levels of LFA-1 on NK cells transduced with GFP only and that with PD-1-GFP (see Fig E7 in this article' s Online Repository at www.jacionline.org). We also checked ILK expression using Western blotting. There was no difference between the NK-GFP and NK-PD-1-GFP cells, and the target cells also exhibited moderate levels of ILK expression that were unaffected by transduction of PD-L1-mCherry (see Fig E8 in this article' s Online Repository at www.jacionline.org). Therefore we conclude that PD-1/PD-L1 engagement disrupts integrin signaling, which is known to be required for LG polarization in NK cells.
DISCUSSION
In this study, we show that PD-1 signaling blocks NK cellmediated immune responses through impairing LG polarization to the NK cell IS. Neither NK-target cell conjugation nor NKtarget cell inhibitory IS formation was blocked by PD-1 engagement. Although the specific role of PD-1 can vary in different cell types and different disease settings, 8 we show that PD-1 functions as an inhibitory receptor in NK cells similar to its action in cytotoxic T cells and other lymphocytes during LGs and the center of the synapse. Cells were stained with anti-perforin (green for LG staining) and phalloidin (red for F-actin staining). NK cells were identified by perforin staining and marked by dashed lines. IS was identified by accumulated F-actin combining with differential interference contrast (DIC) images. In ADCC assays (Fig 4, B) NK cells were pretreated with rituximab to trigger CD16 signaling. Scale bars 5 5 mm. The mean distance of the perforin cluster to the IS in each NK-target cell conjugate (represented by individual data points) was calculated as average values and SDs shown by horizontal lines. ****P < .0001, Student t test.
chronic viral infections and cancers, 39 as well as chronic antigen stimulation. 40 The engagement of PD-1 expressed in the NK cells with its cognate natural ligand, PD-L1, expressed on NKsensitive target cells inhibited both forms of NK-mediated cytotoxicity: NC and ADCC. Furthermore, engagement of PD-1 blocked ILK-mediated integrin outside-in signaling, which can account for inhibition of LG polarization of NK cells and the consequent inhibition of cytotoxicity.
Our results reveal a number of unexpected features of PD-1 signaling on NK cell cytotoxicity. First, it remains controversial whether inhibitory receptors alter IS stability. Some previous studies have suggested that inhibitory receptors destabilize the NK cell IS, rendering the NK cell to disengage from its target before it can successfully initiate a cytolytic attack. 41, 42 This concept also gained support from experiments with mouse CD4 1 T cells, in which continued PD-1/PD-L1 interactions destabilized adhesion of self-reactive CD4
1 T cells in the pancreas by inhibiting the TCR-driven ''stop signals,'' 11 and PD-1/PD-L1 binding blocked stable synapse formation on the glasssupported lipid bilayers containing PD-L1 molecules. 36 However, these observations are in contrast to the finding of long-term (>40 minutes) PD-1/PD-L1 interactions that promoted stable IS formation in virus-specific CD8 1 T cells in lymphocytic choriomeningitis virus clone 13 (a strain that establishes persistent viral infection)-infected mice. 43 Nevertheless, in this study, we demonstrate that NK cells can form a stable IS, even when the inhibitory signaling dominates. The discrepancy can be explained by the differential effect of PD-1 signaling on CD8 1 cytotoxic lymphocytes (including NK and CD8 1 T cells) and CD4 1 T cells caused by different downstream signaling cascades mediated by PD-1 engagement between these cell types.
Indeed, inhibitory receptor signaling does not block accumulation of activating receptors. 44 This has been shown with 2B4 and CD2 at inhibitory synapses with target cells 44 and with the minimal combination of the activation ligand human IgG 1 Fc (a ligand for the low-affinity Fc receptor FcgRIIIA, also known as CD16) and HLA-E (a ligand for inhibitory receptor CD94/ NKG2A). 37 Recently, using a newly developed vertical cell pairing system, we showed formation of a stable inhibitory IS after engaging PD-1 expressed on NK cells with PD-L1-expressing target cells, 28 supporting the idea that stable inhibitory IS formation occurs during inhibitory signaling in NK cells. These results await further validation with a large sample size but bring into the question whether inhibitory receptor signaling acts through destabilization of the IS in NK cells or through other unidentified molecular mechanisms. Our data strongly support the notion that NK cells can form a stable inhibitory synapse, even when inhibitory signaling dominates. However, further studies will check whether PD-1 signaling affects the accumulation of activating receptors and the activating synapse in human primary NK cells.
The current study shows that PD-1 signaling does not decrease the percentage of NK-target cell conjugation. Usually, cell adhesion is the initial step in the immune response. 33, 45, 46 After effector-target cell conjugation, the immunoreceptor starts to trigger immune signaling, either activation or inhibition. For initiating inhibition signaling, the current dogma is that blocking early signaling (eg, adhesion) with an inhibitory receptor will be more effective than blocking the late phase of immune signaling. A previous study showed that the PD-1 antibody CT-011 enhanced immune complex formation between NK and target cells, suggesting that PD-1 might affect NK cell adhesion. 16 Unexpectedly, our data showed that PD-1 inhibitory signaling preferentially blocked integrin-mediated LG polarization without affecting NK-target cell adhesion or cell-cell conjugation. This discrepancy can be explained by different NK cell types and experimental methods, as well as the different strategies used to deliver PD-1 signaling.
It is well characterized that for cytotoxic killing, integrin molecules in cytotoxic lymphocytes possess both inside-out signaling (conjugate formation) and outside-in signaling (LG polarization). 47, 48 Our data suggest that PD-1 preferentially impairs the LFA-1-dependent outside-in signaling pathway rather than the inside-out signaling pathway in NK cells. This differs from recent studies in T cells that showed PD-1 engagement with its physiologic ligand inhibited T-cell adhesion. 49, 50 LFA-1-dependent outside-in signaling in T cells requires inside-out signaling to enhance LG polarization. 24 This is different from that of LFA-1 in human primary resting NK cells, in which the binding of LFA-1 on NK cells to ICAM-1 on target cells is sufficient to induce polarization of LGs to the NK IS. 22, 23 The different LFA-1 signaling pathways between T and NK cells could explain this discrepancy. 51 Previous studies used CD107a and cytokine production assays to evaluate the effects of PD-1 signaling on NK cells, 15, 17, 18, 52 which is different from the observations in this study. Here we used LG polarization, an earlier event in NK cell cytotoxicity, to assess PD-1 signaling. The fact that PD-1 engagement preferentially blocks LG polarization to the NK cell IS is reminiscent of previous studies showing that inhibitory receptors block signals for LG polarization (by integrin LFA-1) more effectively than signals for degranulation. 51 Using Drosophila cell line S2 transfected with various ligands of human NK cell receptors, previous studies investigated whether inhibitory receptors could block LG polarization and degranulation. These studies showed that LG polarization was highly sensitive to inhibition mediated by killer cell immunoglobulin-like receptor and CD94-NKG2A receptors. 51 However, the previous study did not specifically define the underlying molecular basis of this inhibition. In the current study we discovered that PD-1 signaling specifically blocked polarization of the common integrin-signaling molecule ILK at the NK cell IS. To our knowledge, although PD-1 signaling is well characterized in T cells and Src homology domain 2-containing protein tyrosine phosphatase is the only cellular molecule that directly interacts with immunoreceptor tyrosinebased switch motif domain of PD-1, 8 ILK is a newly identified molecule targeted by PD-1 signaling in this study (Fig 6) . Future studies will confirm this observation in freshly isolated primary NK cells either infected by PD-1 lentivirus or patients' NK cells with high PD-1 expression.
In conclusion, we investigated the role of PD-1 in NK cellmediated cytotoxicity, which reveals the underlying molecular basis of the inhibitory receptor PD-1 in NK cell immune responses. Although PD-1 expression is limited in NK cells from healthy subjects, it is upregulated on NK cells from patients with a variety of chronic diseases. 15, 17, 18, 52, 53 We found that PD-1 engagement by its natural ligand, PD-L1, preferentially blocks LG polarization with concomitant impairment in the polarization of the central integrin signaling molecule ILK at the NK cell IS. Our study uncovered a novel signaling molecule used by PD-1 inhibitory receptor in human NK cells and a relationship between PD-1 and integrin signaling, which sheds lights on harnessing the power of NK cells by targeting a downstream PD-1 signaling molecule for disease treatment in the future or modulating integrin signaling to enhance therapeutic responses to PD-1 blockade in patients with cancer and infectious diseases. 
